IBB - (iShares Nasdaq Biotechnology Index Fund)

 IBBのチャート


 IBBの企業情報

symbol -
会社名
分野(sector)   
産業(industry)   
業種   
概要     
本社所在地 --
代表者氏名
代表者役職名
電話番号 --
設立年月日 --
市場名 --
ipoyear ―年
従業員数 --
url --
nasdaq_url https://www.nasdaq.com/symbol/ibb
adr_tso
EBITDA
終値(lastsale) 115.69
時価総額(marketcap) 9145294500
時価総額
売上高
企業価値(EV)
当期純利益
決算概要

 IBBのテクニカル分析


 IBBのニュース

   Big Biotech Stands Tall Amid Race for Virus Vaccine  2020/07/17 17:07:49 ETF Trends
The iShares Nasdaq Biotechnology ETF (IBB) is among the biotechnology ETFs that are shining this year as companies scramble to develop treatments and vaccines to aid in the fight against the novel coronavirus. IBB, which tracks the Nasdaq Biotechnology Index (NBI), is the largest biotech ETF by assets and while it offers a cap-weighted approach, […] The post Big Biotech Stands Tall Amid Race for Virus Vaccine appeared first on ETF Trends .
   Big Biotech Stands Tall Amid Race for Virus Vaccine | ETF Trends  2020/07/17 17:07:49 ETF Trends
The iShares Nasdaq Biotechnology ETF (IBB) is among the biotechnology ETFs that are shining this year as companies scramble to develop treatments and vaccines to aid
   3 Gilead-Heavy ETFs To Watch Amid The AstraZeneca-Gilead Rumor  2020/06/08 14:10:55 Benzinga
In the race to develop a coronavirus vaccine, AstraZeneca (NYSE: AZN ) and Gilead Sciences (NASDAQ: GILD ) are two of the leading contenders and that could be the starting point of a massive marriage, according to recent reports. News broke Sunday that UK-based AstraZeneca made an initial overture to Gilead, the company behind the remdesivir COVID-19 drug. If the talks progress and a deal is struck, it would be the largest ever in the health care sector. Gildead's closing market value last Friday was north of $97 billion, meaning that if a marriage is consummated, AstraZeneca will be doling out well over $100 billion. With that in mind, here are some Gildead-heavy ETFs to consider over the next few days. iShares Nasdaq Biotechnology ETF (IBB) The iShares Nasdaq Biotechnology ETF (NASDAQ: IBB ) is the largest ETF of … Full story available on Benzinga.com
   Dow spikes 912 points as vaccine progress spurs economic-reopening optimism  2020/05/18 20:02:40 Business Insider
US stocks surged on Monday as Moderna announced that its coronavirus vaccine candidate had shown encouraging progress. In a small number of healthy volunteers, Moderna's vaccine helped create immune responses that may help protect people from being infected with the novel coronavirus. Investors have been closely watching for updates that can provide guidance about economic-reopening efforts, and they were encouraged by Moderna's results. West Texas Intermediate crude oil futures skyrocketed as much as 13%, to $33.32 per barrel. Watch major indexes update live here . US stocks surged on Monday as Moderna announced that its coronavirus vaccine candidate had shown encouraging progress. In a small number of healthy volunteers, Moderna's vaccine helped create immune responses that may help protect people from being infected with the novel coronavirus. The biotech firm is planning to start additional trials immediately and aiming to be ready this fall for potential emergency use of its vaccine.
   The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight  2020/05/10 19:40:37 Benzinga
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) gained about 6% for the week. Large-cap pharma names AstraZeneca plc (NYSE: AZN ) and Novartis AG (NYSE: NVS ) received FDA nods for their heart failure and lung cancer therapies, respectively. After receiving emergency use authorization from the FDA in the U.S., Gilead Sciences, Inc.'s (NASDAQ: GILD ) remdesivir obtained full regulatory approval in Japan. Moderna Inc (NASDAQ: MRNA ) received the OK to proceed with the Phase 2 trial of its mRNA coronavirus vaccine candidate mRNA-1273. The following are the key events and catalysts that biotech investors need to watch in the coming week. Conferences Bank of America Securities 2020 HealthCare Virtual Conference: May 12-14 American Society of Gene and Cell Therapy, or ASGCT, 23rd Virtual Annual Meeting: May 12-15 2020 Society for Investigative Dermatology, or SID, Annual Meeting Virtual Conference: May 13-16 Society for Cardiovascular Angiography and Interventions, or SCAI, 2020 Virtual Conference, Scientific Sessions: May 14-16 PDUFA Dates Clovis Oncology Inc (NASDAQ: CLVS ) awaits the FDA nod for an expanded indication for its cancer therapy Rubraca .
   3 Gilead-Heavy ETFs To Watch Amid The AstraZeneca-Gilead Rumor  2020/06/08 14:10:55 Benzinga
In the race to develop a coronavirus vaccine, AstraZeneca (NYSE: AZN ) and Gilead Sciences (NASDAQ: GILD ) are two of the leading contenders and that could be the starting point of a massive marriage, according to recent reports. News broke Sunday that UK-based AstraZeneca made an initial overture to Gilead, the company behind the remdesivir COVID-19 drug. If the talks progress and a deal is struck, it would be the largest ever in the health care sector. Gildead's closing market value last Friday was north of $97 billion, meaning that if a marriage is consummated, AstraZeneca will be doling out well over $100 billion. With that in mind, here are some Gildead-heavy ETFs to consider over the next few days. iShares Nasdaq Biotechnology ETF (IBB) The iShares Nasdaq Biotechnology ETF (NASDAQ: IBB ) is the largest ETF of … Full story available on Benzinga.com
   Dow spikes 912 points as vaccine progress spurs economic-reopening optimism  2020/05/18 20:02:40 Business Insider
US stocks surged on Monday as Moderna announced that its coronavirus vaccine candidate had shown encouraging progress. In a small number of healthy volunteers, Moderna's vaccine helped create immune responses that may help protect people from being infected with the novel coronavirus. Investors have been closely watching for updates that can provide guidance about economic-reopening efforts, and they were encouraged by Moderna's results. West Texas Intermediate crude oil futures skyrocketed as much as 13%, to $33.32 per barrel. Watch major indexes update live here . US stocks surged on Monday as Moderna announced that its coronavirus vaccine candidate had shown encouraging progress. In a small number of healthy volunteers, Moderna's vaccine helped create immune responses that may help protect people from being infected with the novel coronavirus. The biotech firm is planning to start additional trials immediately and aiming to be ready this fall for potential emergency use of its vaccine.
   The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight  2020/05/10 19:40:37 Benzinga
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) gained about 6% for the week. Large-cap pharma names AstraZeneca plc (NYSE: AZN ) and Novartis AG (NYSE: NVS ) received FDA nods for their heart failure and lung cancer therapies, respectively. After receiving emergency use authorization from the FDA in the U.S., Gilead Sciences, Inc.'s (NASDAQ: GILD ) remdesivir obtained full regulatory approval in Japan. Moderna Inc (NASDAQ: MRNA ) received the OK to proceed with the Phase 2 trial of its mRNA coronavirus vaccine candidate mRNA-1273. The following are the key events and catalysts that biotech investors need to watch in the coming week. Conferences Bank of America Securities 2020 HealthCare Virtual Conference: May 12-14 American Society of Gene and Cell Therapy, or ASGCT, 23rd Virtual Annual Meeting: May 12-15 2020 Society for Investigative Dermatology, or SID, Annual Meeting Virtual Conference: May 13-16 Society for Cardiovascular Angiography and Interventions, or SCAI, 2020 Virtual Conference, Scientific Sessions: May 14-16 PDUFA Dates Clovis Oncology Inc (NASDAQ: CLVS ) awaits the FDA nod for an expanded indication for its cancer therapy Rubraca .
   Spherix stock soars after option executed for technology in patent for methods to treat coronavirus infection  2020/03/06 15:09:00 Yahoo Finance
Shares of Spherix Inc. soared 21% in active morning trading Friday, after the biotechnology company said it executed an exclusive option agreement with the University of Maryland, Baltimore for the technology in the patent for "Methods of Treating Coronavirus Infection." Trading volume swelled to 2.2 million shares, already more than the full-day average of 1.2 million shares. The company said the invention was made with support awarded by the National Institutes of Health, which has certain rights in the invention. Under terms of the option, Spherix said it has until the end of May to execute a license agreement for commercial development. The stock has lost 23% over the past three months, while the iShares Nasdaq Biotechnology ETF has slipped 2.5% and the S&P 500 has shed 6.9%.
   The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO  2020/01/12 22:05:52 Benzinga
Activity in the biotech space is likely to pick up this week. Events are likely to be headlined by the annual JPMorgan Healthcare Conference. Biotech stocks closed 2019 with gains, although they underperformed relative to the broader market. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) closed up 25.2% in 2019 compared to the S&P 500's 29% jump. The new year is likely to bring several challenges for biotech stocks, the chief among them being a hard political stance on drug pricing ahead of the year's elections. The following are key catalysts that could take the spotlight this week. Conferences 38th Annual JPMorgan Healthcare Conference: Jan. 13-16 in San Francisco, California. Adcom Meetings A joint Tuesday meeting of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will discuss Nektar Therapeutics' (NASDAQ: NKTR ) NDA for oxycodegol , a NME … Full story available on Benzinga.com
   3 Gilead-Heavy ETFs To Watch Amid The AstraZeneca-Gilead Rumor  2020/06/08 14:10:55 Benzinga
In the race to develop a coronavirus vaccine, AstraZeneca (NYSE: AZN ) and Gilead Sciences (NASDAQ: GILD ) are two of the leading contenders and that could be the starting point of a massive marriage, according to recent reports. News broke Sunday that UK-based AstraZeneca made an initial overture to Gilead, the company behind the remdesivir COVID-19 drug. If the talks progress and a deal is struck, it would be the largest ever in the health care sector. Gildead's closing market value last Friday was north of $97 billion, meaning that if a marriage is consummated, AstraZeneca will be doling out well over $100 billion. With that in mind, here are some Gildead-heavy ETFs to consider over the next few days. iShares Nasdaq Biotechnology ETF (IBB) The iShares Nasdaq Biotechnology ETF (NASDAQ: IBB ) is the largest ETF of … Full story available on Benzinga.com
   Dow spikes 912 points as vaccine progress spurs economic-reopening optimism  2020/05/18 20:02:40 Business Insider
US stocks surged on Monday as Moderna announced that its coronavirus vaccine candidate had shown encouraging progress. In a small number of healthy volunteers, Moderna's vaccine helped create immune responses that may help protect people from being infected with the novel coronavirus. Investors have been closely watching for updates that can provide guidance about economic-reopening efforts, and they were encouraged by Moderna's results. West Texas Intermediate crude oil futures skyrocketed as much as 13%, to $33.32 per barrel. Watch major indexes update live here . US stocks surged on Monday as Moderna announced that its coronavirus vaccine candidate had shown encouraging progress. In a small number of healthy volunteers, Moderna's vaccine helped create immune responses that may help protect people from being infected with the novel coronavirus. The biotech firm is planning to start additional trials immediately and aiming to be ready this fall for potential emergency use of its vaccine.
   The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight  2020/05/10 19:40:37 Benzinga
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) gained about 6% for the week. Large-cap pharma names AstraZeneca plc (NYSE: AZN ) and Novartis AG (NYSE: NVS ) received FDA nods for their heart failure and lung cancer therapies, respectively. After receiving emergency use authorization from the FDA in the U.S., Gilead Sciences, Inc.'s (NASDAQ: GILD ) remdesivir obtained full regulatory approval in Japan. Moderna Inc (NASDAQ: MRNA ) received the OK to proceed with the Phase 2 trial of its mRNA coronavirus vaccine candidate mRNA-1273. The following are the key events and catalysts that biotech investors need to watch in the coming week. Conferences Bank of America Securities 2020 HealthCare Virtual Conference: May 12-14 American Society of Gene and Cell Therapy, or ASGCT, 23rd Virtual Annual Meeting: May 12-15 2020 Society for Investigative Dermatology, or SID, Annual Meeting Virtual Conference: May 13-16 Society for Cardiovascular Angiography and Interventions, or SCAI, 2020 Virtual Conference, Scientific Sessions: May 14-16 PDUFA Dates Clovis Oncology Inc (NASDAQ: CLVS ) awaits the FDA nod for an expanded indication for its cancer therapy Rubraca .
   Spherix stock soars after option executed for technology in patent for methods to treat coronavirus infection  2020/03/06 15:09:00 Yahoo Finance
Shares of Spherix Inc. soared 21% in active morning trading Friday, after the biotechnology company said it executed an exclusive option agreement with the University of Maryland, Baltimore for the technology in the patent for "Methods of Treating Coronavirus Infection." Trading volume swelled to 2.2 million shares, already more than the full-day average of 1.2 million shares. The company said the invention was made with support awarded by the National Institutes of Health, which has certain rights in the invention. Under terms of the option, Spherix said it has until the end of May to execute a license agreement for commercial development. The stock has lost 23% over the past three months, while the iShares Nasdaq Biotechnology ETF has slipped 2.5% and the S&P 500 has shed 6.9%.
   The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO  2020/01/12 22:05:52 Benzinga
Activity in the biotech space is likely to pick up this week. Events are likely to be headlined by the annual JPMorgan Healthcare Conference. Biotech stocks closed 2019 with gains, although they underperformed relative to the broader market. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) closed up 25.2% in 2019 compared to the S&P 500's 29% jump. The new year is likely to bring several challenges for biotech stocks, the chief among them being a hard political stance on drug pricing ahead of the year's elections. The following are key catalysts that could take the spotlight this week. Conferences 38th Annual JPMorgan Healthcare Conference: Jan. 13-16 in San Francisco, California. Adcom Meetings A joint Tuesday meeting of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will discuss Nektar Therapeutics' (NASDAQ: NKTR ) NDA for oxycodegol , a NME … Full story available on Benzinga.com

 twitter  (公式ツイッターやCEOツイッターなど)